Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9BYJ9
UPID:
YTHD1_HUMAN
Alternative names:
Dermatomyositis associated with cancer putative autoantigen 1
Alternative UPACC:
Q9BYJ9; Q8N3G5; Q8TBT1; Q96AN4; Q96S57; Q9BTI7; Q9NX79
Background:
YTH domain-containing family protein 1, also known as Dermatomyositis associated with cancer putative autoantigen 1, plays a pivotal role in RNA metabolism. It specifically recognizes and binds N6-methyladenosine (m6A)-containing mRNAs, influencing their stability and processing. This protein is involved in the degradation of m6A-containing mRNAs, cellular differentiation, learning and memory formation in the hippocampus, axon guidance, and the regulation of antigen cross-presentation in myeloid dendritic cells.
Therapeutic significance:
Understanding the role of YTH domain-containing family protein 1 could open doors to potential therapeutic strategies.